Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AstraZeneca
AstraZeneca
Activities:
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Analysis
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Ingredients
Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Digital
Brainomix’s e-Lung better identifies high risk lung fibrosis patients
WRVS was able to predict both short and long-term patient outcomes, including lung function decline and survival
Research & Development
AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion
The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Therapeutic: datopotamab deruxtecan for breast cancer
Of all the various forms of breast cancer, triple negative is the most aggressive subtype
Research & Development
Fasenra could initiate remission in patients with EGPA, study finds
MANDARA Phase III data highlights remission as an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with monthly subcutaneous injections of Fasenra
Subscribe now